Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), a protein that enables a key step in the control of plasma low density lipoprotein cholesterol (LDLC) levels.
The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany. The company is headquartered in Copenhagen, with research operations centered in Aarhus, Denmark.